



(51) International Patent Classification:
C12N 15/86 (2006.01)

(21) International Application Number:
PCT/NL2023/050525

(22) International Filing Date:
10 October 2023 (10.10.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2033264 10 October 2022 (10.10.2022) NL

(71) Applicant: **AMARNA HOLDING B.V.** [NL/NL]; J.H. Oortweg 21, 2333 CH Leiden (NL).

(72) Inventors: **VAN DIEMEN, Ferdy Rudolf**; J.H. Oortweg 21, 2333 CH Leiden (NL). **DE GIER, Laurens Christiaan**; J.H. Oortweg 21, 2333 CH Leiden (NL). **DE HAAN, Petrus Theodorus**; J.H. Oortweg 21, 2333 CH Leiden (NL).

(74) Agent: **ALGEMEEN OCTROOI- EN MERKENBU-
REAU B.V.**; P.O. Box 645, 5600 AP Eindhoven (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: COMPOSITION AND METHOD FOR THE PRODUCTION OF POLYOMAVIRAL VECTOR PARTICLES




Fig. 4

(57) **Abstract:** The present invention relates to a composition for use in the production of polyomaviral vector particles, the composition comprising a first DNA construct comprising recombinant DNA and a polyomaviral intergenic region, wherein said first DNA construct does not comprise polyomaviral functional coding sequences and bacterial plasmid sequences, and a second DNA construct comprising polyomaviral functional coding sequences encoding functional polyomaviral capsid proteins, wherein said second DNA construct cannot be encapsidated into the polyomaviral vector particles. The present invention further relates to a method for the production of polyomaviral vector particles using the first and second DNA constructs and the polyomaviral vector particles for use as a medicament, preferably for use in the treatment of genetic disorders and immunity-associated diseases.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*